Analytical Study of the Quality Status of National Drug Sampling and Testing in 2022
10.3870/j.issn.1004-0781.2024.10.031
- VernacularTitle:2022年国家药品抽检质量状况分析研究
- Author:
Jialiang ZHU
1
;
Ting SUN
;
Bilian CHEN
;
Nana RONG
;
Chong WANG
;
Zengyao HU
Author Information
1. 中国食品药品检定研究院,北京 100050
- Keywords:
National drug sampling and testing;
Quality status;
Drug quality risks
- From:
Herald of Medicine
2024;43(10):1706-1710,后插1
- CountryChina
- Language:Chinese
-
Abstract:
Objective To understand and assess the quality status of national drug sampling inspection in 2022 and the possible risks of drug quality.Methods With the aim of identifying issues and preventing risks,a sampling model of"dispersed sampling,centralized inspection,exploratory research,and comprehensive evaluation"was used to review the historical inspection data of national drug sampling.The overall quality and potential risks of national drug sampling in 2022 were analyzed,with a focus on identifying and examining the main quality problems and risks.Results The average pass rate of the sampling inspection in 2022 was 99.4% .The overall safety situation of China's post-marketing drug quality is stable and manageable,indicating that the drug quality is at a high level.Conclusions By carrying out exploratory studies related to drug safety,authenticity,and efficacy,national sampling plays an important role in comprehensively evaluating the quality status of drugs.It aids in improving the quality control level of drug varieties and industry standards,strengthening quality and safety supervision,combating illegal practices such as adulteration and falsification,and providing public warnings about drug safety.
